T1	Participants 80 105	relapsed Hodgkin disease.
T2	Participants 247 286	relapsed or refractory Hodgkin disease.
T3	Participants 358 383	tertiary referral center.
T4	Participants 393 524	Twenty-four patients (twelve of whom were controls) treated with high-dose chemotherapy and autologous bone marrow transplantation.
T5	Participants 1794 1869	patients with relapsed Hodgkin disease who received intensive chemotherapy.
